Suprachoroidal CLS-TA for non-infectious uveitis: an open-label, safety trial (AZALEA).

ABSTRACT:

Purpose

To evaluate local and systemic safety of suprachoroidal (SC) triamcinolone acetonide injectable suspension (CLS-TA) injections in subjects with non-infectious uveitis (NIU).

Design

Open-label, prospective multicentre safety study.

Participants

Thirty-eight subjects with NIU, with and without macular oedema (MO).

Methods

Treatment consisted of two suprachoroidal injections of CLS-TA 4 mg, 12 weeks apart. Best-corrected visual acuity (BCVA), adverse event (AE) assessment, ophthalmic examinations and optical coherence tomography (OCT) were conducted every 4 weeks for 24 weeks. Blood samples were analysed for plasma triamcinolone acetonide (TA) concentrations.

Main outcome measures

The main outcome measure was frequency of AEs. Other endpoints includ

SUBMITTER: Henry CR 

PROVIDER: S-EPMC9132856 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature